A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer

REFERENCES

• ACS: American Cancer Society. Cancer Facts and Figures. 2007
   Google Scholar
• Hensley M. L., Reichman B. S. Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Crit. Rev. Oncol. Hematol. 1998; 28: 121–128
   PubMed Web of Science ®Google Scholar
• EBCTCG: Polychemotherapy for Early Stage Breast Cancer: An Overview of the Randomised Trials. Early Breast Cancer Trialist' Collaborative Group. Lancet, 352: 930–942
   PubMedGoogle Scholar
• Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J. Soc. Gynecol. Investig. 2001; 8: S60–64
   PubMedGoogle Scholar
• Blumenfeld Z., Ritter M., Shen-Orr Z., , Inhibin A, et al. concentrations in the sera of young women during and after chemotherapy for lymphoma: correlation with ovarian toxicity. Am. J. Reprod. Immunol. 1998; 39: 33–40
   PubMed Web of Science ®Google Scholar
• Rajpert-De Meyts E., Jorgensen N., Graem N., Muller J., Cate R., Skakkebaek M. Expression of anti-Mullerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. Journal of Clinical Endocrinology and Metabolism 1999; 84: 3836–3844
   PubMed Web of Science ®Google Scholar
• Hudson P., Douglas I., Donahoe P., Cate R., Epstein J., Pepinsky R., MacLaughlin D. An immunoassay to detect human Mullerian inhibiting substance in males and females during normal development. Journal of Clinical Endocrinology and Metabolism 1990; 70: 16–22
   PubMed Web of Science ®Google Scholar
• Lee M., Donahoe P., Hasegawa T., Silverman B., Crist B., Best S., Hasegawa Y., Noto R., Scheonfeld D., MacLaughlin D. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. Journal of Clinical Endocrinology and Metabolism 1996; 81: 571–576
   PubMed Web of Science ®Google Scholar
• La Marca A., Stabile G., Carducci Artenisio A., Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Human Reproduction 2006; 12: 3103–3107
   Google Scholar
• Anders C., Snyder S., Barrier R., Demark-Wahnefried W., Welch R., Marcom P., Shaw H., Chui S., Blackwell K. Inhibin A and B as predictive markers for chemotherapy-induced premature ovarian failure (POF) among pre-menopausal women with operable breast cancer. Breast Cancer Research and Treatment 2005; 94, 28th Annual San Antonio Breast Cancer Symposium (Suppl 1)
   Web of Science ®Google Scholar
• Brucker P., Yost K., Cashy J., et al. General Population and Cancer Patient Norms for the Functional Assessment of Cancer Therapy-General (FACT-G) per Erratum. Evalulations and the Health Professions 2005; 28(3)370
   Web of Science ®Google Scholar
• Host H., Lund E. Age as a Prognostic Factor in Breast Cancer. Cancer 1986; 57: 2217–2221
   PubMed Web of Science ®Google Scholar
• Holli K., Isola J. Effect of age on the survival of breast cancer patients. Eur. J. Cancer 1997; 33: 425–428
   PubMed Web of Science ®Google Scholar
• Kollias J., Elston C. W., Ellis I. O., et al. Early-onset breast cancer–histopathological and prognostic considerations. Br. J. Cancer 1997; 75: 1318–1323
   PubMed Web of Science ®Google Scholar
• Walshe J., Denduluri N., Swain S. Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology 2006; 24: 5769–5779
   PubMed Web of Science ®Google Scholar
• Bines J., Oleske D. M., Cobleigh M. A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 1996; 14: 1718–1729
   PubMed Web of Science ®Google Scholar
• Petrek J. A., Naughton M. J., Case D., Paskett E. D., Naftalis E. J., Singletary S. E., Sukumvanich P. Incidence, Time Course and Determinants of Menstrual Bleeding after Breast Cancer Treatment: A Prospective Study. Journal of Clinical Oncology 2006; 24: 1045–1051
   PubMed Web of Science ®Google Scholar
• Cobleigh M. A. Amenorrhea Following Adjuvant Chemotherapy for Breast Cancer. Proc. Am. Soc. Clin. Oncol. 1995; 14(115)158
   Google Scholar
• Partridge A., Gelber S., Peppercorn J., et al. Web-Based Survey of Fertility Issues in Young Women With Breast Cancer. Journal of Clinical Oncology 2004; 22: 4174–4183
   PubMed Web of Science ®Google Scholar
• Anderson R., Themmen A., Al-Qahtani A., Groome N., Cameron D. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve of premenopausal women with breast cancer. Human Reproduction 2006; 21: 2583–2592
   PubMed Web of Science ®Google Scholar
• Stone E., Slack R., Novielli A., et al. Rate of chemotherapy-related amenorrhea associated with adjuvant adriamycin and cytoxan and adriamycin followed by taxane in the early stage breast cancer. Breast Cancer Research and Treatment 2000; 64
   Google Scholar
• Alton J., Jacobs L., Fox K. Chemotherapy-related amenorrhea (CRA) in breast cancer survivors: Impact of taxanes on ovarian function. Breast Cancer Research and Treatment 2004; 88
   Web of Science ®Google Scholar
• Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine 2005; 352: 2302–2313
   PubMed Web of Science ®Google Scholar
• Lutchman Singh K., Muttukrishna S., et al. Predictors of ovarian reserve in young women with breast cancer. Br. J. Cancer 2007; 96(12)1808–1816
   PubMed Web of Science ®Google Scholar
• Bianco A., De Placido S., Pagliarulo C., Fasano S., D'Istria M., De Sio L., Ricciardi I., Delrio G. Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer. Chemioterapia 1985; 4: 252–255
   PubMedGoogle Scholar